Soleno Therapeutics Inc (SLNO)

NASDAQ
Currency in USD
Disclaimer
29.8300
+0.0700(+0.24%)
Closed
After Hours
29.8500+0.0200(+0.067%)
Trading near 52-week High
Day's Range
29.160030.4200
52 wk Range
0.850030.4200
Prev. Close
29.76
Open
29.16
Day's Range
29.16-30.42
52 wk Range
0.85-30.42
Volume
224,406
Average Vol. (3m)
1,178,469
1-Year Change
2,853.47%
Shares Outstanding
30,499,352
Fair Value
Unlock
Dividends Payment Streak
Unlock
Analysts
Technical
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
45.5000
Upside +52.5310%

People Also Watch

3.4300
TPST
-2.42%
17.490
METC
+4.73%
4.10
KA
+3.27%
51.81
MOD
+5.32%
How do you feel today about SLNO?
Vote to see community's results!
or

Soleno Therapeutics Inc Company Profile

Soleno Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare diseases. The Company’s lead candidate, Diazoxide Choline Extended-Release tablets (DCCR), a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is being evaluated in a phase III clinical development program. DCCR is a potent ATP-sensitive potassium (KATP) channel activator. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. DCCR’s mode of action with targets in the brain, pancreas and fat tissue has the potential to broadly impact complex diseases like PWS to reduce appetite, reduce food seeking, improve satiety, improve insulin and leptin resistance, and reduce body fat. The Company has a Fast-Track designation for DCCR in PWS and orphan designation for the drug in the United States and the European Union.